• Locally advanced or metastatic and/or unresectable HCC

• WHO/ECOG performance status of 0 or 1

• BCLC stage B (that is not eligible for locoregional therapy) or stage C. Child-Pugh Score class A

• At least one measurable target lesion

• co-infected with HBV and HCV are not eligible

• Adequate organ and bone marrow function measured during the screening period

• Must not have received prior systemic therapy for intermediate, advanced, or metastatic HCC.

• Disease that is not amenable to curative surgical and/or locoregional therapies. For participants who received locoregional therapy for HCC, locoregional therapy must have been completed ≥ 28 days prior to the baseline scan for the current study.